original article Wien Klin Wochenschr (2017) 129:517–526 DOI 10.1007/s00508-016-1162-y Progress in eradication of HCV in HIV positive patients with signiﬁcant liver ﬁbrosis in Vienna Sebastian Steiner · Theresa Bucsics · Philipp Schwabl · Mattias Mandorfer · Bernhard Scheiner · Maximilian Christopher Aichelburg · Katharina Grabmeier-Pﬁstershammer · Peter Ferenci · Michael Trauner · Markus Peck-Radosavljevic · Thomas Reiberger Received: 18 August 2016 / Accepted: 19 December 2016 / Published online: 27 January 2017 © The Author(s) 2017. This article is available at SpringerLink with Open Access. Summary of SOF/LDV and 60% of 2D/3D patients prior to Aim We aimed to investigate the efﬁcacy of interferon anti-HCV treatment due to expected DDIs. We ob- and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) served sustained virologic response (SVR) rates of and ritonavir boosted paritaprevir/ombitasvir with 100% in patients treated with SOF/LDV (19/19) and or without dasabuvir (2D/3D) regimens in a real-life 2D/3D (14/14). One 2D/3D patient was lost to follow- cohort of human immunodeﬁciency virus/hepatitis up, while two SOF/LDV patients died during ther- C virus (HIV/HCV) coinfected patients. The study apy from non-treatment-related causes. They were focused on efﬁcacy, need for changes in antiretroviral excluded from the analysis. Between baseline and fol- therapy (ART) due to
Wiener klinische Wochenschrift – Springer Journals
Published: Jan 27, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera